The Kitchen is empty.
Accrol Group Holdings 36.05p £115.0m (ACRL.L)
The independent tissue converter, announces a trading update ahead of its Final Results for the year ended 30 April 2023, scheduled to be released in September. Revenue increased 52% to £241.8m (FY22: £159.5m), and adjusted EBITDA is expected to be in line with market expectations. Adjusted net debt is lower than last year at £26.8m (FY22: £27.5m). The Board expects the Group's results for FY23 to be in line with current market expectations.
Anglesey Mining 1.65p £4.9m (AYM.L)
The UK mining company focused on Zinc, Copper and lead deposits in the Parys Mountain region in North Wales announces its intention to raise gross proceeds of c.£1m by proposed placing of new ordinary shares at a price of 1.5p per share. The Issue Price represents a discount of c.28.57% to the closing price of 2.10p on 15 May 2023. The use of proceeds include; Commence drilling of the Northern Copper Zone; Continuing to advance the permitting and Environmental Impact and Social Assessment of the Parys Mountain mine; Commence baseline studies for the Grängesberg Iron Ore Mine in Sweden; and for general working capital purposes.
Atlantic Lithium 33.78p £205.8m (ALL.L)
The funded African-focussed lithium exploration and development company targeting to deliver Ghana's first lithium mine, announces the appointments of Keith Muller as Chief Executive Officer and Len Kolff as Head of Business Development & Chief Geologist, both effective immediately. Mr Muller has over 20 years of operational and leadership experience and a background in hard rock lithium mining and processing. Mr Kolff will be responsible for the ongoing exploration activities of the Company and identifying and developing growth opportunities.
Boohoo Group 40.8p £517.5m (BOO.L)
The global fashion brand announces its final results for the 12 months ended 28 February 2023. Revenue decreased 11% to £1.769bn (2022: £1.98bn), gross profit reduced by 14% to £895.2m (2022: £1.041bn) and adjusted EBITDA decreased 49% to £63.3m. Net cash at year-end of £5.9m. During the period, the Group completed a £91m capital expenditure investment to support growth ambitions. For the year ending 28 February 2024 (FY24), revenues are expected to be between flat and a decline of 5% vs. the prior year, however adjusted EBITDA is expected to be between £69m to £78m, in line with marker expectations. Over the medium term, the group expect adjusted EBITDA margin of 6-8%.
Hercules Site Services 37p £23.1m (HERC.L)
A technology enabled labour supply company for the UK infrastructure sector, provides a trading update for the six months ended 31 March 2023. Revenue is expected to be over £37m for the first six months, representing an increase of c. 85% year-on-year (H1 2022: £19.9m). The Group is trading in line with expectations.
Renew Holdings 728.5p £576.5m (RNWH.L)
The engineering services group supporting the maintenance and renewal of critical UK infrastructure, announces its interim results for the six months ended 31 March 2023. Group revenue increased 13.9% to £471.8m (HY22: £414.3m), adjusted operating profit and profit before tax increased by 20.9% and 20.9% to £26.9m and £26.3m respectively. The Group order book currently stands at £890m (HY22: £771m). The Board remain confident that full year results will be in line with expectations.
Shoe Zone 202.5p £96.7m (SHOE.L)
A company focused on the sale of a wide range of footwear nationwide announces its interim results for the 26 weeks to 1st April 2023. Revenue for Company increased 7.9% to £75.4m (2022 H1: £69.9m), although profit before tax decreased by c.50% to £1.5m (2022 H1: £3.1m). The Company holds net cash of £12.9m (2022 H1: £13.9m). Shoe Zone opened 17 new stores, 6 refits and 41 closed down during the period. Full year results are in line with market expectations.
SmartSpace Software 45.5p £13.2m (SMRT.L)
The provider of Integrated Space Management Software for smart buildings and commercial spaces announces its audited final results for the year ended 31 January 2023. Revenue grew by 48% to £5.06m (FY22: £3.41m), and annual recurring revenue (ARR) increased 25% to £5.59m (FY22: £4.23m). The Group reported an Adjusted EBITDA loss of £0.77m (FY22: £2.38m). Cash balance at the end of the period of £1.96m (FY22: £2.76m). During the period, 807 new customers were added contributing £0.9m of new ARR. The Group continues its international expansion with launch of fully localised products into Taiwan, China and Germany.
Sureserve Group 124.25p £206.5m (SUR.L)
The Social Housing Energy Services Group, announces its unaudited interim results for the six-month period ended 31 March 2023. Revenue increased by 23% to £155.3m (H1 2022: £126.2m), EBITA increased 41.2% to £7.2m (H1 2022: £5.1m) and its profit before tax increased 55.8% to £6.7m (H1 2022: £4.3m). The Company holds net cash of £14.4m (31 March 2022: £11.8m). The Company announced 44 contract wins in H1 with a total contract value of £93.2m (H1 2022: £101.2m). Sureserve have good visibility of revenue streams with 98% of FY23 expected revenue covered by the order book.
Zenova Group 5.25p £4.9m (ZED.L)
A provider of fire safety and heat management technology solutions announces that Clastrom (its sub-distributors in Spain and Germany) has placed a first order for the FX500 aerosol fire extinguisher for an initial 40,000 units (with a retail value of £800k). Clastrom's first delivery of 10,000 units will be supplied by the 15th July 2023 and the rest to be delivered before the year end. The Company anticipate increasing production and sales via our expanding sub distributor network.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
